-
Cancer Treatment Reports Oct 1983
Topics: Adult; Aged; Breast Neoplasms; Female; Humans; Middle Aged; Mitolactol; Platelet Count
PubMed: 6627238
DOI: No ID Found -
Cancer Treatment Reports Apr 1984Antitumor activity has been documented in this pilot study utilizing mitolactol in patients with advanced carcinoma of the cervix. These results may in part be explained... (Comparative Study)
Comparative Study
Antitumor activity has been documented in this pilot study utilizing mitolactol in patients with advanced carcinoma of the cervix. These results may in part be explained by optimal patient selection; however, the results do encourage further testing of this hexitol in this disease.
Topics: Adult; Carcinoma, Squamous Cell; Drug Evaluation; Female; Humans; Lung Neoplasms; Middle Aged; Mitolactol; Neoplasm Recurrence, Local; Time Factors; Uterine Cervical Neoplasms
PubMed: 6713421
DOI: No ID Found -
Cancer Treatment Reports Jan 1982
Topics: Adult; Aged; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; Mitolactol; Neoplasm Metastasis
PubMed: 7053257
DOI: No ID Found -
Therapia Hungarica (English Edition) 1978
Topics: Adult; Aged; Carcinoma, Squamous Cell; Female; Humans; Male; Middle Aged; Mitolactol; Papilloma; Urinary Bladder Neoplasms
PubMed: 684658
DOI: No ID Found -
Cancer Metastasis Reviews Dec 2010The authors compared N0 with N+ cases in neoadjuvant chemotherapy regression and recurrence. During a 12-year period, 180 consecutive oral squamous cell cancer patients... (Review)
Review
The authors compared N0 with N+ cases in neoadjuvant chemotherapy regression and recurrence. During a 12-year period, 180 consecutive oral squamous cell cancer patients were observed. Of these patients, 78 were N0 and 102 N+ stages. The drugs used were as follows: bleomycin, vincristine, methotrexate, and mitolactol. After three courses of chemotherapy, the regression (complete response (CR), partial response (PR), and no response (NR)) and side effect rate were determined. All patients were operated on and observed for the number and localization of recurrences during 3 year follow-up time. The N0 cases came from T2-3, while N+ was from T2-4a (AJCC 2002). The regression in the N0 group was CR 46%, PR 53%, and NR 1%; but in the N+ group, it was CR 12%, PR 72%, and NR 16%. The regression rate was significantly higher (p = 0.00025) for N0 group than N+ group. The regression rate for T3 N0 was significantly higher (p = 0.055) than for T3 N+ cases. In the N0 stage, the regression rate was significantly higher (p = 0.0174) for T2 than T3. In N+ stage, there was no significant difference (p = 0.183) for T2-4a. The side effects were slight. The recurrence rate for the N0 group was significantly lower (15%, p = 0.000069), while for N+ group, it was 59%. The dependence in the T3 cases was also significant (p = 0.009) in the 3-year tumor-free survival. The N stage seems a more important prognostic factor for chemotherapy response and recurrence rate than the T stage. Stage III can be divided into subgroups without metastasis (III.a) and with metastasis (III.b.), based on significant difference in regression and recurrence rate.
Topics: Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Humans; Lymphatic Metastasis; Male; Middle Aged; Mouth Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction
PubMed: 20842409
DOI: 10.1007/s10555-010-9259-7 -
Cancer Treatment Reports 1981
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Mitolactol; Thrombocytopenia
PubMed: 6271397
DOI: No ID Found -
Cancer Treatment Reports Jul 1986
Clinical Trial
Topics: Adult; Aged; Carcinoma, Squamous Cell; Clinical Trials as Topic; Drug Evaluation; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mitolactol
PubMed: 3521849
DOI: No ID Found -
Neoplasma 1976Mitolactol (Dibromodulcitol "DBD"; RlobromolR) an alkylating agent was applied in a clinical series of twenty advanced or relapsing cases of malignant tumors of the...
Mitolactol (Dibromodulcitol "DBD"; RlobromolR) an alkylating agent was applied in a clinical series of twenty advanced or relapsing cases of malignant tumors of the orofacial region and the larynx. It was administered orally in a mean total dose of 127 mg/kg/30 days. In 45% of the patients the treatment resulted in a diminution of tumors by more than 50%, with remission lasting 1-4 months. 30% of the patients responded by a retreat of the tumor volume smaller than 50%, while no therapeutic effect was noted in 25% of the patients, or the objective finding proved to be worse. Subsequent radiotherapy improved the results, and remissions which followed combined chemo-radiotherapy were prolonged up to 9 months. The effect of DBD treatment proved better in orofacial than in laryngeal carcinoma.
Topics: Adult; Aged; Body Weight; Drug Evaluation; Facial Neoplasms; Female; Hemorrhage; Humans; Laryngeal Diseases; Laryngeal Neoplasms; Male; Middle Aged; Mitolactol; Mouth Neoplasms; Recurrence; Remission, Spontaneous
PubMed: 1004654
DOI: No ID Found -
Journal of Clinical Oncology : Official... Apr 1990
Topics: Breast Neoplasms; Female; Humans; Leukemia, Myeloid, Acute; Mitolactol; Myelodysplastic Syndromes
PubMed: 2313338
DOI: 10.1200/JCO.1990.8.4.751 -
Cancer Treatment Reports Feb 1986
Topics: Adenocarcinoma; Adult; Aged; Drug Evaluation; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Mitolactol
PubMed: 3948194
DOI: No ID Found